Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
Summary
This translational work could lead to future clinical trials for TBI patients.The data from this collaboration are anticipated to inform the development of Biosplices DYRK inhibitor class in the treatment of degenerative neurological conditions, including various tauopathies. TBI, along with Alzheimers Disease, certain Frontotemporal Dementias and Amyotrophic Lateral Sclerosis (ALS) are in a class of neurological disorders characterized by an aggregation of harmful tau proteins. Because the DYRK protein plays a key role in the formation of harmful tau protein aggregates, Biosplice believes that its potent and selective DYRK inhibitors can potentially constitute effective, first-in-class therapies.We are pleased to collaborate with Roskamp in this exciting research program endeavoring to address a great unmet need for effective therapies for TBI, said Dr. Yusuf Yazici, Chief Medical Officer of Biosplice. These kinases play pivotal roles in cell cycle regulation, splicing, and neurodevelopment, marking them as critical targets for therapeutic intervention in a range of diseases, including osteoarthritis, cancer, neurological disorders, and diabetes. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3) and cirtuvivint for numerous cancers, with a broad pre-clinical pipeline that encompasses Alzheimers disease, diabetes and other degenerative conditions.